NCT01145209View on ClinicalTrials.gov

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 1, 2010

Primary Completion Date

October 31, 2017

Study Completion Date

September 15, 2023

Conditions
Small Lymphocytic LymphomaCLL (Chronic Lymphocytic Leukemia)
Interventions
DRUG

Fludarabine Phosphate

Given IV

BIOLOGICAL

Ofatumumab

Given IV

DRUG

Cyclophosphamide

Given IV

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

University of Virginia

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT01145209 - Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL | Biotech Hunter | Biotech Hunter